3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
27
Neoplasms
9
Kidney Neoplasms
9
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Lung Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Melanoma
2
Kidney Diseases
2
Advanced Solid Tumors
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Interventions
Sunitinib
4
avelumab
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
palbociclib
1
cabozantinib
1
atezolizumab
1
VMBP protocol
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Nivolumab
1
Cystoscopy
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Diseases
×
Axitinib
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts